The price of Selecta Biosciences Inc. (NASDAQ: SELB) closed at $1.29 in the last session, up 2.38% from day before closing price of $1.26. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 503401 shares were traded.
We take a closer look at SELB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.70 and its Current Ratio is at 6.70. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on June 14, 2022, Reiterated its Buy rating but revised its target price to $5 from $6 previously.
On June 06, 2022, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $7.
On June 15, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $10.BTIG Research initiated its Buy rating on June 15, 2021, with a $10 target price.
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 28 when Brunn Carsten sold 2,692 shares for $1.66 per share. The transaction valued at 4,470 led to the insider holds 537,867 shares of the business.
Brunn Carsten sold 4,768 shares of SELB for $8,810 on Sep 02. The President and CEO now owns 540,559 shares after completing the transaction at $1.85 per share. On Jun 13, another insider, COX CARRIE SMITH, who serves as the Director of the company, bought 130,000 shares for $1.15 each. As a result, the insider paid 149,799 and bolstered with 212,881 shares of the company.
As of this moment, Selecta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.60 while its Price-to-Book (P/B) ratio in mrq is 2.30.
Stock Price History:
Over the past 52 weeks, SELB has reached a high of $3.64, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 1.6040, while the 200-Day Moving Average is calculated to be 1.5077.
According to the various share statistics, SELB traded on average about 870.08K shares per day over the past 3-months and 835.08k shares per day over the past 10 days. A total of 152.85M shares are outstanding, with a floating share count of 114.59M. Insiders hold about 0.50% of the company’s shares, while institutions hold 48.80% stake in the company. Shares short for SELB as of Oct 13, 2022 were 7.8M with a Short Ratio of 7.68M, compared to 5.91M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 5.11% and a Short% of Float of 7.65%.
The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.01 for the current quarter, with a high estimate of $0.12 and a low estimate of -$0.09, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.05 and low estimates of -$0.15.
Analysts are recommending an EPS of between $0.25 and $0.05 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is -$0.36, with 7 analysts recommending between -$0.06 and -$0.55.
According to 7 analysts, the current quarter’s revenue is expected to be $25.21M. It ranges from a high estimate of $45M to a low estimate of $10.5M. As of the current estimate, Selecta Biosciences Inc.’s year-ago sales were $24.43M, an estimated increase of 3.20% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $11.68M, a decrease of -61.00% less than the figure of $3.20% in the same quarter last year. There is a high estimate of $18M for the next quarter, whereas the lowest estimate is $5.12M.
A total of 7 analysts have provided revenue estimates for SELB’s current fiscal year. The highest revenue estimate was $123.44M, while the lowest revenue estimate was $89.3M, resulting in an average revenue estimate of $110.17M. In the same quarter a year ago, actual revenue was $85.08M, up 29.50% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $46.53M in the next fiscal year. The high estimate is $85.83M and the low estimate is $9.61M. The average revenue growth estimate for next year is down -57.80% from the average revenue estimate for this year.